A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11).

Li ChuYun ChenQi LiuFei LiangShengping WangQuan LiuHui YuXianghua WuJunhua ZhangJiaying DengDashan AiZhengfei ZhuYongzhan NieKuaile Zhao

Published in: The oncologist (2021)

Apatinib has potential as an effective and safe treatment for patients with chemotherapy-refractory ESCC whose primary tumors are controlled and without severe invasion of trachea, bronchi, or major blood vessels.

Keyphrases

phase ii study
locally advanced
rectal cancer
squamous cell carcinoma
open label
radiation therapy
early onset
randomized controlled trial
combination therapy
chemotherapy induced
risk assessment
drug induced
climate change